---
layout: post
title: "Long Term Follow-Up After Administration of Human Gene Therapy Products; Guidance for Industry; Availability"
date: 2026-02-05 19:08:19 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-01710
original_published: 2020-01-30 00:00:00 +0000
significance: 8.00
---

# Long Term Follow-Up After Administration of Human Gene Therapy Products; Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** January 30, 2020 00:00 UTC
**Document Number:** 2020-01710

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled "Long Term Follow-Up After Administration of Human Gene Therapy Products." The guidance document provides sponsors, who are developing a human gene therapy (GT) product, recommendations regarding the design of long term follow- up (LTFU) observational studies for the collection of data on delayed adverse events following administration of a GT product. This guidance finalizes the draft guidance of the same title dated July 2018 and supersedes the document entitled "Guidance for Industry: Gene Therapy Clinical Trials--Observing Subjects for Delayed Adverse Events" dated November 2006. This guidance also supplements the guidance entitled "Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus during Product Manufacture and Patient Follow-up; Guidance for Industry."

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/01/30/2020-01710/long-term-follow-up-after-administration-of-human-gene-therapy-products-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2020-01710

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
